A licensed clinician reviews your history typically within 48 hours
Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man
Your healthcare provider evaluates how you tolerate each dose level before recommending progression, considering factors like nausea severity, appetite suppression effectiveness, and individual gastrointestinal response
This means both platforms rely on observable clinical factors, BMI history, and metabolic markers without exploring whether a patient's genetic architecture might predispose them toward stronger or weaker GLP-1 receptor sensitivity, body-weight regulation pathways, or metabolic flexibility
Expecting noticeable scalp health improvements by 8 weeks, visible new growth by 4 months, and meaningful density changes by 6-8 months creates a structured framework for evaluation
Its part of a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1), which mimic a hormone in your body that helps regulate blood sugar, insulin levels, and appetite